Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) — Analysis Summary
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) has a market cap of $1.82B with year-over-year revenue growth of +26.9%. Net margin stands at -863.4%. The stock trades at a P/E ratio of -3.5.
Key Takeaways
- Revenue changed +26.9% year-over-year
- Net margin of -863.4%
- P/E ratio of -3.5
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, RXRX posted revenue growth of +26.9% and trades at a P/E of -3.5.
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -367.3x — earnings do not cover interest payments
Operating margin at -991.7% — severe operating losses
Net margin at -945.9% — losses exceed revenue (possible one-time charges)
Revenue fell 26.5% vs the prior period.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
600
Headquarters
SALT LAKE CITY, UT
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.